Michael R. Hayden is Director at Xenon Pharmaceuticals Inc. (XENE). They have made 12 open-market trades across 4 companies since 2017, most recently 2026-08-24.
CIK 0001352908
11 open-market purchases totalling $7.0M since 2017, against 1 sale. Across 8 scored buys the stock is up 3.6% at ninety days, and 2.0 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ABCL | 1,373,397 | $17.0M |
| XENE | 116,206 | $3.9M |
| AUPH | 95,000 | $1.6M |
| IONS | 24,000 | $1.0M |
| ETNB | 61,538 | $913K |
| Total | $24.4M |
Shares reported on the most recent Form 4, priced at the 2026-08-24 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 45% | 55% | 50% |
| Avg Move | +4.0% | +7.4% | +3.6% |
| Alpha | +3.5% | +6.4% | -2.0% |
| Scored | 11 | 11 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABCL | BUY | 2026-08-24 | 2026-08-24 | $10.64 | $570K | +4.8% | +13.1% | — |
| ABCL | BUY | 2026-08-12 | 2026-08-14 | $10.37 | $481K | +8.7% | -0.8% | — |
| IONS | BUY | 2026-07-30 | 2026-07-31 | $52.94 | $1.1M | +7.4% | +14.6% | — |
| IONS | BUY | 2025-05-01 | 2025-05-02 | $31.86 | $478K | -1.9% | +2.7% | +29.4% |
| IONS | BUY | 2024-12-23 | 2024-12-26 | $36.22 | $272K | -6.6% | -6.7% | -13.7% |
| ABCL | BUY | 2023-09-22 | 2023-09-26 | $4.91 | $98K | -6.6% | -12.5% | +22.0% |
| ABCL | BUY | 2023-08-08 | 2023-08-09 | $5.90 | $177K | -7.8% | -10.6% | -27.3% |
| ETNB | BUY | 2022-03-30 | 2023-03-30 | $13.87 | $2.1M | -10.5% | +5.2% | +17.3% |
| ABCL | SELL | 2021-06-22 | 2021-06-22 | $25.50 | $2.5M | -2.5% | -23.7% | -1.7% |
| ABCL | BUY | 2020-12-15 | 2020-12-17 | $20.00 | $1.5M | -16.5% | -0.2% | -26.2% |
| ETNB | BUY | 2019-11-11 | 2019-11-13 | $16.00 | $300K | +47.8% | +52.7% | +37.8% |
| XENE | BUY | 2017-08-14 | 2017-08-14 | $2.75 | $41K | +25.0% | +24.0% | -10.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.